I agree but perhaps tend to disagree...how about this heading to the whole Newsletter. What does this tell you? It indicates to me the initial findings are good, if not exceptionally good. Vaxinia is is the jewel in Imugene's crown. It's their focus. Good results here across an array of solid tumours supersede anything anyone in the field of immunotherapy is or could hope to achieve.
Watch this space...OVER RECENT MONTHS WE HAVE BEEN FOCUSSING ON THE CLINICAL DEVELOPMENT OF VAXINIA.
Leslie Chong Imugene CEO & Managing Director
Opinions only
I agree but perhaps tend to disagree...how about this heading to...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.002(3.92%) |
Mkt cap ! $387.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.3¢ | 5.0¢ | $605.4K | 11.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 455000 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 1913821 | 7 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |